Compare Repligen Corporation Common Stock (RGEN) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Starbucks Corp — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while Starbucks Corp trades at $94.05 (market cap $106.31B). The key difference: Starbucks Corp is far larger — about 9.4× Repligen Corporation Common Stock's market cap, and Starbucks Corp pays a 2.7% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Starbucks Corp for 190 Days on average.
| RGEN | SBUX | |
|---|---|---|
Market Cap | $11.31B | $106.31B |
Volume | 1,216,919 | 6,776,814 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $108.55 |
52-Week Low | $102.87 | $79.60 |
Typical Hold Time | 0 Days | 190 Days |
Enterprise Value | $11.20B | $125.13B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Starbucks (SBUX) trades at $92.00, down 0.31% on the day, with technical indicators showing bearish momentum. The company reported mixed quarterly results, missing Q4 2025 EPS estimates but beating in Q1 and Q2 2026. Recent news highlights store closures and strategic restructuring, while analyst consensus remains positive with a $115.50 price target. Financial trends show revenue growth to $37.18B in 2025 but declining net income margins from 11.46% in 2023 to 4.99% in 2025.
SBUX faces execution risks from store optimization and labor relations, but strong brand equity and analyst buy ratings suggest long-term recovery potential. The stock's high P/E ratio of 53.18 indicates premium valuation expectations. Near-term pressure from restructuring costs contrasts with dividend stability and international expansion opportunities through partnerships in Asia.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
